Draft the Best Tools for Face Milling

Import 02/11/2016Bakalářská práce se zabývá výběrem vhodné frézy pro obrábění rovinných ploch. Výběr frézy probíhal ve společnosti JCEE s.r.o. v Lanškrouně. Práce je rozdělena na teoretickou a praktickou část. Teoretická část představuje firmu a historii obrábění. Dále odvětví ve strojírenství a její druhy. Konec první části se zabývá obecnou problematikou frézování tj. stroje, nástroje, druhy frézování, druhy materiálů fréz. Praktická část řeší samotný výběr vhodné frézy s cílem dosažení požadovaného povrchu. Pro experiment byly k dispozici tři frézy. Testování probíhalo na stroji od firmy Hurco GmbH. Podle nejlepší drsnosti povrchu, ceny VBD a efektivity obrábění se vybrala nejvhodnější fréza.The bachellor's thesis deals with selection of appropriate milling tool for machining of flat surfaces. Selection took place at company JCEE s.r.o. in Lanškroun. Thesis is split to practical and theoretical parts. Theoretical part introduces the company and history of machining, branches and types of machining industries. The end of the first part deals with general issues of milling - machines, tools, milling categories, categories of milling tools materials. Practical part deals with the selection process itself with the aim of achievement of required surface. There were 3 milling tools available for the experiment. Testing was performed on machine be company Hurco GmbH. Milling tool was selected according to best surface roughness, price of VBD and efectivity of machining.346 - Katedra obrábění, montáže a strojírenské metrologievelmi dobř

Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma

[Aim]: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed.[Results]: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events.[Conclusion]: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1.This work was supported by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Reinterpretation of fossil reproductive structures Zlivifructus microtriasseris (Normapolles complex, Fagales) from the Czech and Polish Late Cretaceous

Flowers and fruits of Zlivifructus microtriasseris, originally described as Caryanthus microtriasseris from the late Turonian to Santonian of the South Bohemian Basins and the late Coniacian to early Santonian of the North Sudetic Basin, are reinterpreted here. Zlivifructus microtriasseris is represented by small, flat fruits, round in outline with persistent perianths, which are fused basally, forming the hypanthium. The hypanthium extends for more than two-thirds of the fruit. Tepals leave scars indicating their insertion. Lateral attachment scars of tepals and medial attachment scars are immediately adjacent to each other, with indistinct boundaries forming a ring. The androecium consists of four stamens. The fruit shows the unilocular nature of the nut with a single seed. Lateral faces of the fruit show two parallel ribs or ridges, running from the base of the fruit to the margin of the hypanthium. The surface of the fruit bears irregularly shaped cells. Zlivifructus microtriasseris differs from species assigned to genus Caryanthus Friis 1983 in the presence of four stamen scars, and in having two lateral ribs in the face of the fruit. Zlivifructus microtriasseris differs from the type species Zlivifructus vachae in size of the fruit; shape of the fruit; perianth and attachment scars of tepals. A probabilistic classification method to differentiate between the two fruit species based on their size is proposed

Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma

Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov)